Format

Send to

Choose Destination
Int Urol Nephrol. 2020 Jan 1. doi: 10.1007/s11255-019-02362-4. [Epub ahead of print]

Efficacy and safety of a low monthly dose of intravenous iron sucrose in peritoneal dialysis patients.

Author information

1
Department of Nephrology, General Hospital of Thessaloniki Papageorgiou, Periferiaki Odos Thessalonikis, 56403, Nea Efkarpia, Greece. mitsopouloss@yahoo.com.
2
Department of Nephrology, General Hospital of Thessaloniki Papageorgiou, Periferiaki Odos Thessalonikis, 56403, Nea Efkarpia, Greece.

Abstract

PURPOSE:

Scientific data regarding intravenous iron supplementation in peritoneal dialysis (PD) patients are scarce. In attempting to administer the minimum monthly IV iron dose that could improve erythropoiesis, we wanted to assess the safety and efficacy of monthly maintenance intravenous administration of 100 mg iron sucrose in PD patients.

METHODS:

In a 9-month prospective study, all clinically stable PD patients received intravenously 200 mg of iron sucrose as a loading dose, followed by monthly doses of 100 mg for five consecutive months. Levels of hemoglobin (Hb), ferritin, transferrin saturation (TSAT), reticulocyte hemoglobin content (CHr) and C-reactive protein (CRP) were measured before each administration and 3 months after the last iron infusion. Also, doses of concurrent erythropoietin administration were recorded.

RESULTS:

Eighteen patients were eligible for the study. Mean levels of Hb and ferritin increased significantly (from 10.0 to 10.9 mg/dL, p = 0.01 and from 143 to 260 ng/mL, p = 0.005), as well as the increase in TSAT levels approached borderline significance (from 26.2 to 33.1%, p = 0.07). During the 6 months of iron administration, the erythropoietin dose was reduced in five patients and discontinued in one. During the 3 months following the last iron infusion, three of them again raised the erythropoietin dose to previous levels. None of the patients experienced any side effects related to IV iron administration.

CONCLUSIONS:

A monthly maintenance intravenous dose of 100 mg iron sucrose may be a practical, effective, and safe in the short term, treatment of anemia in PD patients resulting in improved hemoglobin levels, iron indices, and erythropoietin response.

KEYWORDS:

Albumin; Anemia; Erythropoietin; Ferritin; Transferrin saturation

PMID:
31894555
DOI:
10.1007/s11255-019-02362-4

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center